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Abstract: 
 AIMS: Evidences of benefits of telemedicine in T1DM patients on continuous 
subcutaneous insulin infusion (CSII) treatment are limited. Aims: 1) to analyse the 
differences in clinical and psychological variables between subjects with T1DM on 
CSII treatment who were included in a Telecare (TC) program, and subjects with 
T1DM on CSII treatment who received Conventional care (CC); 2) Perform a cost 
analysis of the use of telemedicine in DM1 patients treated with CSII (TC versus CC). 
 METHODS and PARTICIPANTS: Cross-over randomized clinical trial with duration 
of 18 months. 51 patients signed informed consent. Participants were randomly 
assigned to receive TC program or CC during 6 months, and after a 3 months wash-
out period, patients changed to CC or to TC respectively. TC program included 
monthly visits using an Internet platform. CC comprised face-to-face visits every 
three months. Sociodemographic, clinical and psychological data was measured at 
the beginning and at the end of TC and CC. The direct and indirect costs were also 
measured. T Student was performed to assess differences between first and last 
visits in both groups (TC / CC).  
 RESULTS: Patients with telemedicine at the end of treatment, have fewer 
hyperglycemia / week, less distress and greater adherence. Considering both 
direct and indirect costs, the cost per treatment (TC / CC) is similar. 
 CONCLUSIONS: Telemedicine has significant implications for clinical and 
psychological variables and has the same cost (total) than the conventional 
treatment. Therefore, it can be a useful alternative for treatment of DM1 patients 
with CSII. However, studies with a larger sample size are needed. 
